Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx

Chen, Ping Ho; Yy, Wang; Lan, Ting-Hsun; Chan, Leong‐Perng; Yuan, Shyng‐Shiou F.

doi:10.3390/cancers13133268

Cited by 4 publications

(1 citation statement)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These specific SNPs were chosen based on previous reports indicating their correlations with the risk or progression of cancers or other diseases and their impacts on the activity or expression of MAOB. 23 , 24 , 25 , 26 Allelic discrimination of the MAOB rs1799836 (assay ID: C_8878790_10), rs3027452 (assay ID: C_15763403_10), rs6651806 (assay ID: C_29047318_10) and rs6324 (assay ID: C_11617922_10) SNPs was performed using a TaqMan SNP Genotyping Assay, utilizing the ABI StepOnePlus™ Real‐Time PCR System (ThermoFisher Scientific). Detailed procedures for DNA genotyping are described in our previously published study.…”

Section: Methodsmentioning

confidence: 99%

MAOB expression correlates with a favourable prognosis in prostate cancer, and its genetic variants are associated with the metastasis of the disease

Huang,

Hsieh,

Hsiao

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Monoamine oxidase B (MAOB), a neurotransmitter‐degrading enzyme, was reported to reveal conflicting roles in various cancers. However, the functional role of MAOB and impacts of its genetic variants on prostate cancer (PCa) is unknown. Herein, we genotyped four loci of MAOB single‐nucleotide polymorphisms (SNPs), including rs1799836 (A/G), rs3027452 (G/A), rs6651806 (A/C) and rs6324 (G/A) in 702 PCa Taiwanese patients. We discovered that PCa patients carrying the MAOB rs6324 A‐allele exhibited an increased risk of having a high initial prostate‐specific antigen (iPSA) level (>10 ng/mL). Additionally, patients with the rs3027452 A‐allele had a higher risk of developing distal metastasis, particularly in the subpopulation with high iPSA levels. In a subpopulation without postoperative biochemical recurrence, patients carrying the rs1799836 G‐allele had a higher risk of developing lymph node metastasis and recurrence compared to those carrying the A‐allele. Furthermore, genotype screening in PCa cell lines revealed that cells carrying the rs1799836 G‐allele expressed lower MAOB levels than those carrying the A‐allele. Functionally, overexpression and knockdown of MAOB in PCa cells respectively suppressed and enhanced cell motility and proliferation. In clinical observations, correlations of lower MAOB expression levels with higher Gleason scores, advanced clinical T stages, tumour metastasis, and poorer prognosis in PCa patients were noted. Our findings suggest that MAOB may act as a suppressor of PCa progression, and the rs3027452 and rs1799836 genetic variants of MAOB are linked to PCa metastasis within the Taiwanese population.

show abstract

Section: Methodsmentioning

confidence: 99%

MAOB expression correlates with a favourable prognosis in prostate cancer, and its genetic variants are associated with the metastasis of the disease

Huang,

Hsieh,

Hsiao

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

The highs and lows of monoamine oxidase as molecular target in cancer: an updated review

Hâncu,

Giuchici,

Furdui-Lința

et al. 2024

Mol Cell Biochem

View full text Add to dashboard Cite

The global burden of cancer as a major cause of death and invalidity has been constantly increasing in the past decades. Monoamine oxidases (MAO) with two isoforms, MAO-A and MAO-B, are mammalian mitochondrial enzymes responsible for the oxidative deamination of neurotransmitters and amines in the central nervous system and peripheral tissues with the constant generation of hydrogen peroxide as the main deleterious ancillary product. However, given the complexity of cancer biology, MAO involvement in tumorigenesis is multifaceted with different tumors displaying either an increased or decreased MAO profile. MAO inhibitors are currently approved for the treatment of neurodegenerative diseases (mainly, Parkinson’s disease) and as secondary/adjunctive therapeutic options for the treatment of major depression. Herein, we review the literature characterizing MAO’s involvement and the putative role of MAO inhibitors in several malignancies, and also provide perspectives regarding the potential biomarker role that MAO could play in the future in oncology.

show abstract

Selective Serotonin Reuptake Inhibitors for Cessation of Betel Quid Use in Patients with Major Depressive Disorder in Taiwan

Hung,

Tu,

Chung

2024

Biomedicines

View full text Add to dashboard Cite

Background/Objectives: Major depressive disorder (MDD) frequently co-occurs with substance use disorders such as alcohol and nicotine use disorders. Comorbid substance use disorders worsen the clinical symptoms of MDD and exacerbate addictive behaviors and presentations. However, the relationship between MDD and betel quid use disorder (BUD) in Taiwan has not been extensively investigated. Methods: We performed this cross-sectional study investigated associations between betel quid use, BUD, and MDD specifically in the Taiwanese population. Long-term betel quid use is a major public health concern, contributing significantly to the high incidence of oral cancers, which rank fifth among the top ten most common cancers in Taiwan. Results: Among patients with MDD, the current BUD prevalence rate was 7.32%, and the lifetime BUD prevalence rate was 15.45%. Patients with comorbid BUD were more likely to have severe alcohol and nicotine dependence disorders and required longer antidepressant treatment. Conclusions: Notably, 16.98% of patients with comorbid BUD who received selective serotonin reuptake inhibitor treatment achieved abstinence. BUD has a detrimental effect on health outcomes in patients with MDD, and selective serotonin reuptake inhibitor treatment may be required to be prolonged for betel quid abstinence therapy to be effective. Additional studies should investigate medication therapies for betel quid addiction disorders.

show abstract

Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx

Cited by 4 publications

References 70 publications

MAOB expression correlates with a favourable prognosis in prostate cancer, and its genetic variants are associated with the metastasis of the disease

MAOB expression correlates with a favourable prognosis in prostate cancer, and its genetic variants are associated with the metastasis of the disease

The highs and lows of monoamine oxidase as molecular target in cancer: an updated review

Selective Serotonin Reuptake Inhibitors for Cessation of Betel Quid Use in Patients with Major Depressive Disorder in Taiwan

Contact Info

Product

Resources

About